Drug intelligence / Profile preview

polyvalent antigen-KLH conjugate vaccine

Development stage
Phase 3
Lead developer
Memorial Sloan Kettering Cancer Center
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of five tumor-associated antigens (TAAs): Globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH). The vaccine is designed to induce antibody responses against these tumor-associated antigens. KLH serves as a hapten carrier and immunostimulant to improve immune recognition of the antigens. The conjugation to KLH is achieved through various methods including covalent attachment using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) for TF(c) and Tn-MUC1, MMCCH linker for Globo H, and reductive amination methods for GM2. The vaccine is typically administered with an immunological adjuvant such as OPT-821 (derived from Quillaja saponaria Molina).

Other names
polyvalent vaccine-KLH conjugate
02

Targets

CA19-9 (Carbohydrate antigen 19-9)

Beyond the preview

Go deeper on polyvalent antigen-KLH conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyvalent antigen-KLH conjugate vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call